A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients
with type 2 diabetes receiving a stable dose of metformin. The anticipated time on study
treatment is 3-12 months and the target sample size is 100-500 individuals.